Pamba (Pamba)

Composition Pharmacodynamics Indications Carefully Contraindications Dosing and Administration Side effects Form release / dosage
Read on
Active substanceAminomethylbenzoic acidAminomethylbenzoic acid
Similar drugsTo uncover
  • Amben
    solution w / m in / in 
    FARMZASCHITA NPC, GP     Russia
  • Pamba
    solution w / m in / in 
    PROFIT FARM, LLC     Russia
    • Dosage form: & nbspSolution for intravenous and intramuscular injection.
    Composition:Per 1 ml:

    Active substance: aminomethylbenzoic acid (Amben) (in terms of anhydrous substance) 10 mg.

    Excipients: sodium chloride 9 mg, water for injection up to 1 ml.

    Description:Pcolorless liquid.
    Pharmacotherapeutic group:hemostatic agent
    ATX: & nbsp

    B.02.A.A.03   Aminomethylbenzoic acid

    Pharmacodynamics:

    Pamba refers to inhibitors of fibrinolysis, synthetic analogues of lysine. By its action, the drug is similar to epsilon-aminocaproic acid, but it is much more effective than it.

    The specific hemostatic effect of Pamba in bleeding due to increased fibrinolysis is associated with blockade of plasminogen activators and partial inhibition of plasmin. Pamba inhibits fibrinolysis, competitively saturating the lysine-binding receptors, through which plasminogen (plasmin) binds to fibrinogen (fibrin). The drug also inhibits biogenic polypeptides-kinins.

    Pamba enhances the detoxifying function of the liver, inhibits antigenigenesis.

    Pharmacokinetics:

    With intravenous administration, the maximum concentration of Pamba in the blood is determined immediately and within 30-45 minutes, after 3 hours the drug disappears from the blood. With intramuscular injection, the maximum concentration of the drug in the blood is determined after 30-60 minutes. Pamba is excreted by the kidneys. With daily urine, more than 70% of unchanged drug is released and only 10-15% - in the form of N-acetylated form, pharmacologically indifferent. If the excretory function of the kidneys is violated, the concentration of Pamba in the blood increases significantly.

    Indications:

    - The conditions under which systemic hyperfibrinolysis develops (overdose of plasminogen activators: streptokinase, urokinase, etc.);

    - with a decrease in the ability to form a hemostatic thrombus (with a violation of procoagulant, platelet or vascular components of hemostasis);

    - with localized hemorrhages due to increased local fibrinolytic activity (after tonsillectomy, operations on the prostate, bladder, menorrhagia);

    - increased fibrinolytic activity of the blood; operations on the brain (including with subarachnoid hemorrhages), operations on the lungs, heart, blood vessels,thyroid and pancreas; after dental interventions, with premature detachment of the normally located placenta, prolonged retention in the uterine cavity of the dead fetus, uterine bleeding; with acute pancreatitis; liver diseases; nasal, gastrointestinal bleeding;

    - prevention of the development of secondary hypophybrinogenemia in massive transfusions of canned blood.

    Contraindications:

    Propensity to thrombosis and thromboembolic diseases, hypersensitivity, hypercoagulable phase of DIC syndrome, vitreous hemorrhage, severe forms of coronary heart disease and cerebral ischemia, with kidney disease with impaired function, pregnancy (first trimester).

    Carefully:Use with caution in cases of cerebral circulation disorders.
    Pregnancy and lactation:

    In preclinical studies aminomethylbenzoic acid did not have a teratogenic effect on animals.

    It is not known whether aminomethylbenzoic acid in breast milk.

    The use of Pamba in the first trimester of pregnancy is contraindicated.

    The use of the drug on late pregnancy and in the period of breastfeeding is possible only in case of emergency and with extreme caution.

    Studies in animals have not demonstrated reproductive toxicity of aminomethylbenzoic acid.

    Dosing and Administration:

    Enter intramuscularly or intravenously struino in doses of 50-100 mg (5-10 ml of a solution of 10 mg / ml).

    If necessary, the introduction can be repeated many times at intervals of not less than 4 hours.

    In acute fibrinolysis, fibrinogen is additionally administered, controlling the fibrinolytic activity of the blood and the content of fibrinogen in it.

    The maximum single dose of the drug is 100 mg (10 ml of a solution of 10 mg / ml). The total (daily) dose and duration of treatment depend on the course of the disease.

    Side effects:

    From the digestive system: vomiting, diarrhea.

    From the cardiovascular system: increase or decrease in blood pressure, tachycardia.

    Local Reactions: thrombophlebitis at the injection site.

    Allergic reactions.

    Other: renal colic, catarrhal phenomena from the upper respiratory tract.

    In some cases, dizziness, orthostatic hypotension, convulsions are observed. In this case, you should reduce the dose or cancel the drug.

    Overdose:An overdose of the drug is extremely rare and is characterized by increased blood coagulability.
    In case of an overdose, intravenous administration of heparin at a dose of 5000 ME and / or cancellation of the drug.
    Interaction:The simultaneous use of large doses of Pamba and other haemostatic agents (eg, etamzilate) can lead to the formation of blood clots on the one hand, by increasing the formation of fibrin under the influence of hemostatics, and on the other hand, due to the slow dissolution of the formed thrombi due to Pamba's anti-plasmin action.
    Special instructions:

    The purpose of the drug requires checking the fibrinolytic activity of the blood and the level of fibrinogen.

    With intravenous administration, coagulogram monitoring is necessary, especially in coronary heart disease, after myocardial infarction, and liver diseases.

    Introduction Pamba can be combined with the introduction of hydrolysates, especially glucose solution, anti-shock solutions.

    In acute fibrinolysis, fibrinogen is additionally administered (the average dose of the latter is 2-4 g, the maximum dose is 8 g).

    Effect on the ability to drive transp. cf. and fur:

    Data on the adverse effect of the drug on the ability to manage vehicles and mechanisms are absent.

    Form release / dosage:

    Solution for intravenous and intramuscular injection, 10 mg / ml.

    Packaging:In ampoules of 5 ml.

    5 ampoules per circuit cell box made of polyvinylchloride film and aluminum foil, or without foil.

    2 contour squares with instructions for the use of the drug in a pack of cardboard.

    Storage conditions:

    In the dark place at a temperature of no higher than 25 ° C.

    Keep out of the reach of children.

    Shelf life:

    3 years.

    Do not use after the expiration date printed on the package.

    Terms of leave from pharmacies:On prescription
    Registration number:LP-003703
    Date of registration:23.06.2016
    Expiration Date:23.06.2021
    The owner of the registration certificate:PROFIT FARM, LLCPROFIT FARM, LLC Russia
    Manufacturer: & nbsp
    Information update date: & nbsp17.08.2016
    Illustrated instructions
      Instructions
      Up